It is still early days for immunotherapeutic strategies. Speaking from the International Conference on Acute Myeloid Leukemia 2017, Estoril, Portugal by the European School of Hematology (ESH), Marion Subklewe, MD, of the University of Munich, Munich, Germany, discusses her interest in pre-clinical data and understanding the mechanism of action of immunotherapy in acute myeloid leukemia. Prof. Subklewe highlights the work on this subject to look forward to at the American Society of Hematology (ASH) 2017 congress.
AML immunotherapy: pre-clinical data to look forward to at ASH 2017
